Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin.

Antimicrobial Agents and Chemotherapy
K StuertzR Nau

Abstract

The release of lipoteichoic acid (LTA) and teichoic acid (TA) from a Streptococcus pneumoniae type 3 strain during exposure to ceftriaxone, meropenem, rifampin, rifabutin, quinupristin-dalfopristin, and trovafloxacin in tryptic soy broth was monitored by a newly developed enzyme-linked immunosorbent assay. At a concentration of 10 microg/ml, a rapid and intense release of LTA and TA occurred during exposure to ceftriaxone (3,248+/-1,688 ng/ml at 3 h and 3,827+/-2,133 ng/ml at 12 h) and meropenem (2,464+/-1,081 ng/ml at 3 h and 2,900+/-1,364 ng/ml at 12 h). Three hours after exposure to rifampin, rifabutin, quinupristin-dalfopristin, and trovafloxacin, mean LTA and TA concentrations of less than 460 ng/ml were observed (for each group, P < 0.01 versus the concentrations after exposure to ceftriaxone). After 12 h of treatment, the LTA and TA concentrations were 463+/-126 ng/ml after exposure to rifampin, 669+/-303 ng/ml after exposure to rifabutin, and 1,236+/-772 ng/ml after exposure to quinupristin-dalfopristin (for each group, P < 0.05 versus the concentrations after exposure to ceftriaxone) and 1,745+/-1,185 ng/ml after exposure to trovafloxacin (P = 0.12 versus the concentration after exposure to ceftriaxone). At 10 microg/m...Continue Reading

References

May 1, 1985·The Journal of Infectious Diseases·E TuomanenA Tomasz
May 1, 1995·The Journal of Infectious Diseases·Y S KimM G Täuber
Jun 1, 1993·The Journal of Infectious Diseases·M E Evans, M Pollack
Dec 1, 1995·Antimicrobial Agents and Chemotherapy·D J MasonV A Gant
Jul 1, 1997·Chemotherapy·H SchmidtR Nau

❮ Previous
Next ❯

Citations

Aug 31, 2001·Clinical and Diagnostic Laboratory Immunology·L M PlitnickE J Gosselin
Aug 6, 2005·Journal of Clinical Microbiology·Monique A S H Mennink-KerstenPaul E Verweij
Oct 24, 2007·Infection and Immunity·Ho Seong SeoMoon H Nahm
Jan 22, 2002·Trends in Neurosciences·Roland Nau, Wolfgang Brück
May 21, 2019·The Journal of Antimicrobial Chemotherapy·Geert H GroeneveldJaap T van Dissel
May 28, 2005·The Journal of Antimicrobial Chemotherapy·Herman MattieJaap T van Dissel
Jun 7, 2014·Frontiers in Cellular Neuroscience·Roland NauHelmut Eiffert
Jul 27, 1999·International Journal of Antimicrobial Agents·P Periti, T Mazzei
Sep 1, 2006·The Journal of Biological Chemistry·Christian DraingSonja von Aulock
Jun 13, 1998·Antimicrobial Agents and Chemotherapy·H SchmidtR Nau
Mar 21, 2007·Antimicrobial Agents and Chemotherapy·Denis GrandgirardStephen L Leib
Feb 19, 2000·Antimicrobial Agents and Chemotherapy·A SmirnovR Nau
Sep 30, 2000·Clinical and Experimental Immunology·G ZyskH Heinz
Dec 9, 2000·FEMS Microbiology Letters·S SelaA Barzilai
Oct 9, 2004·BioTechniques·Jennifer L Nalepka, Edward M Greenfield

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.